Performance of United States serologic assays in the diagnosis of lyme borreliosis acquired in Europe

Clinical Infectious Diseases

Volumn 57, Issue 3, 2013, Pages 333-340

  Branda, John A ^a   Strle, Franc ^b   Strle, Klemen ^a   Sikand, Nikhil ^a   Ferraro, Mary Jane ^a   Steere, Allen C ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

Author keywords

Borrelia burgdorferi; C6; Diagnosis; Lyme; VlsE

Indexed keywords

IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN M ANTIBODY;

ACRODERMATITIS CHRONICA ATROPHICANS; ANTIBIOTIC THERAPY; ANTIBODY DETECTION; ANTIBODY RESPONSE; ARTICLE; BORRELIA AFZELII; BORRELIA BURGDORFERI; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHEMA CHRONICUM MIGRANS; EUROPE; FALSE POSITIVE RESULT; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; IMMUNOGLOBULIN BLOOD LEVEL; LYME DISEASE; MAJOR CLINICAL STUDY; NONHUMAN; PREDICTIVE VALUE; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SEROLOGY; SKIN BIOPSY; UNITED STATES;

BORRELIA BURGDORFERI; C6; DIAGNOSIS; LYME; VLSE;

EUROPE; HUMANS; LYME DISEASE; SENSITIVITY AND SPECIFICITY; SEROLOGIC TESTS; TRAVEL; UNITED STATES;

EID: 84880337935     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cit235     Document Type: Article

References (40)

1. Wang G, van Dam AP, Schwartz I, Dankert J. Molecular typing of Borrelia burgdorferi sensu lato: taxonomic, epidemiological, and clinical implications. Clin Microbiol Rev 1999; 12:633-53.
2. Mathiesen DA, Oliver JH Jr, Kolbert CP, et al. Genetic heterogeneity of Borrelia burgdorferi in the United States. J Infect Dis 1997; 175:98-107.
3. Anderson JF, Magnarelli LA, LeFebvre RB, et al. Antigenically variable Borrelia burgdorferi isolated from cottontail rabbits and Ixodes dentatus in rural and urban areas. J Clin Microbiol 1989; 27:13-20.
4. Magnarelli LA, Anderson JF, Johnson RC, Nadelman RB, Wormser GP. Comparison of different strains of Borrelia burgdorferi sensu lato used as antigens in enzyme-linked immunosorbent assays. J Clin Microbiol 1994; 32:1154-8.
5. Berger BW, MacDonald AB, Benach JL. Use of an autologous antigen in the serologic testing of patients with erythema migrans of Lyme disease. J Am Acad Dermatol 1988; 18:1243-6.
6. Karlsson M. Antibody response against autologous and heterologous isolates of Borrelia burgdorferi in four patients with Lyme neuroborreliosis. Eur J Clin Microbiol Infect Dis 1991; 10:742-5.
7. Wilske B. Diagnosis of Lyme borreliosis in Europe. Vector Borne Zoonotic Dis 2003; 3:215-27.
8. Hauser U, Krahl H, Peters H, Fingerle V, Wilske B. Impact of strain heterogeneity on Lyme disease serology in Europe: comparison of enzyme-linked immunosorbent assays using different species of Borrelia burgdorferi sensu lato. J Clin Microbiol 1998; 36:427-36.
9. Norman GL, Antig JM, Bigaignon G, Hogrefe WR. Serodiagnosis of Lyme borreliosis by Borrelia burgdorferi sensu stricto, B. garinii, and B. afzelii Western blots (immunoblots). J Clin Microbiol 1996; 34:1732-8.
10. Cinco M, Murgia R, Ruscio M, Andriolo B. IgM and IgG significant reactivity to Borrelia burgdorferi sensu stricto, Borrelia garinii and Borrelia afzelii among Italian patients affected by Lyme arthritis or neuroborreliosis. FEMS Immunol Med Microbiol 1996; 14:159-66.
11. Dressler F, Ackermann R, Steere AC. Antibody responses to the three genomic groups of Borrelia burgdorferi in European Lyme borreliosis. J Infect Dis 1994; 169:313-8.
12. Hauser U, Lehnert G, Lobentanzer R, Wilske B. Interpretation criteria for standardized Western blots for three European species of Borrelia burgdorferi sensu lato. J Clin Microbiol 1997; 35:1433-44.
13. Hauser U, Lehnert G, Wilske B. Validity of interpretation criteria for standardized Western blots (immunoblots) for serodiagnosis of Lyme borreliosis based on sera collected throughout Europe. J Clin Microbiol 1999; 37:2241-7.
14. Robertson J, Guy E, Andrews N, et al. A European multicenter study of immunoblotting in serodiagnosis of Lyme borreliosis. J Clin Microbiol 2000; 38:2097-102.
15. Recommendations for test performance and interpretation from the Second National Conference on Serologic Diagnosis of Lyme Disease. MMWR Morb Mortal Wkly Rep 1995; 44:590-1.
16. Petrovic M, Vogelaers D, Van Renterghem L, Carton D, De Reuck J, Afschrift M. Lyme borreliosis - a review of the late stages and treatment of four cases. Acta Clin Belg 1998; 53:178-83.
17. Zhang JR, Hardham JM, Barbour AG, Norris SJ. Antigenic variation in Lyme disease borreliae by promiscuous recombination of VMP-like sequence cassettes. Cell 1997; 89:275-85.
18. Liang FT, Alvarez AL, Gu Y, Nowling JM, Ramamoorthy R, Philipp MT. An immunodominant conserved region within the variable domain of VlsE, the variable surface antigen of Borrelia burgdorferi. J Immunol 1999; 163:5566-73.
19. Liang FT, Philipp MT. Analysis of antibody response to invariable regions of VlsE, the variable surface antigen of Borrelia burgdorferi. Infect Immun 1999; 67:6702-6.
20. Tjernberg I, Schon T, Ernerudh J, Wistedt AC, Forsberg P, Eliasson I. C6-peptide serology as diagnostic tool in neuroborreliosis. APMIS 2008; 116:393-9.
21. Tjernberg I, Kruger G, Eliasson I. C6 peptide ELISA test in the serodiagnosis of Lyme borreliosis in Sweden. Eur J Clin Microbiol Infect Dis 2007; 26:37-42.
22. Jansson C, Carlsson SA, Granlund H, Wahlberg P, Nyman D. Analysis of Borrelia burgdorferi IgG antibodies with a combination of IgG ELISA and VlsE C6 peptide ELISA. Clin Microbiol Infect 2005; 11:147-50.
23. Cinco M, Murgia R. Evaluation of the C6 enzyme-linked immunoadsorbent assay for the serodiagnosis of Lyme borreliosis in north-eastern Italy. New Microbiol 2006; 29:139-41.
24. Stanek G, Fingerle V, Hunfeld KP, et al. Lyme borreliosis: clinical case definitions for diagnosis and management in Europe. Clin Microbiol Infect 2011; 17:69-79.
25. Cerar T, Ogrinc K, Cimperman J, Lotric-Furlan S, Strle F, Ruzic-Sabljic E. Validation of cultivation and PCR methods for diagnosis of Lyme neuroborreliosis. J Clin Microbiol 2008; 46:3375-9.
26. Cerar D, Cerar T, Ruzic-Sabljic E, Wormser GP, Strle F. Subjective symptoms after treatment of early Lyme disease. Am J Med 2010; 123:79-86.
27. Stupica D, Lusa L, Ruzic-Sabljic E, Cerar T, Strle F. Treatment of erythema migrans with doxycycline for 10 days versus 15 days. Clin Infect Dis 2012; 55:343-50.
28. Branda JA, Aguero-Rosenfeld ME, Ferraro MJ, Johnson BJ, Wormser GPSteere AC. 2-tiered antibody testing for early and late Lyme disease using only an immunoglobulin G blot with the addition of a VlsE band as the second-tier test. Clin Infect Dis 2010; 50:20-6.
29. Branda JA, Linskey K, Kim YA, Steere AC, Ferraro MJ. Two-tiered antibody testing for Lyme disease with use of 2 enzyme immunoassays, a whole-cell sonicate enzyme immunoassay followed by a VlsE C6 peptide enzyme immunoassay. Clin Infect Dis 2011; 53:541-7.
30. Marangoni A, Moroni A, Accardo S, Cevenini R. Borrelia burgdorferi VlsE antigen for the serological diagnosis of Lyme borreliosis. Eur J Clin Microbiol Infect Dis 2008; 27:349-54.
31. Bunikis J, Olsen B, Westman G, Bergstroom S. Variable serum immunoglobulin responses against different Borrelia burgdorferi sensu lato species in a population at risk for and patients with Lyme disease. J Clin Microbiol 1995; 33:1473-8.
32. Liang FT, Aberer E, Cinco M, et al. Antigenic conservation of an immunodominant invariable region of the VlsE lipoprotein among European pathogenic genospecies of Borrelia burgdorferi sl. J Infect Dis 2000; 182:1455-62.
33. Gottner G, Schulte-Spechtel U, Wilske B. Heterogeneity of the immunodominant surface protein VlsE among the three genospecies of Borrelia burgdorferi pathogenic for humans. Int J Med Microbiol 2004; 293(suppl 37):172-3.
34. Tjernberg I, Sillanpaa H, Seppala I, Eliasson I, Forsberg P, Lahdenne P. Antibody responses to Borrelia IR(6) peptide variants and the C6 peptide in Swedish patients with erythema migrans. Int J Med Microbiol 2009; 299:439-46.
35. Sillanpaa H, Lahdenne P, Sarvas H, et al. Immune responses to borrelial VlsE IR(6) peptide variants. Int J Med Microbiol 2007; 297:45-52.
36. Porwancher RB, Hagerty CG, Fan J, et al. Multiplex immunoassay for Lyme disease using VlsE1-IgG and pepC10-IgM antibodies: improving test performance through bioinformatics. Clin Vaccine Immunol 2011; 18:851-9.
37. Centers for Disease Control and Prevention (CDC), Division of Vector-borne Infectious Diseases. Reported cases of Lyme disease by year, United States, 2002-2011. Available at: http://www.cdc.gov/lyme/stats/chartstables/ casesbyyear.html. Accessed 6 December 2012.
38. Steere AC, McHugh G, Damle N, Sikand VK. Prospective study of serologic tests for Lyme disease. Clin Infect Dis 2008; 47:188-95.
39. Bacon RM, Biggerstaff BJ, Schriefer ME, et al. Serodiagnosis of Lyme disease by kinetic enzyme-linked immunosorbent assay using recombinant VlsE1 or peptide antigens of Borrelia burgdorferi compared with 2-tiered testing using whole-cell lysates. J Infect Dis 2003; 187:1187-99.
40. Wilske B, Zöller L, Brade V, et al. MIQ 12 Lyme-borreliose. In: Mauch HLütticken R, eds. Qualitätsstandards in der mikrobiologisch infektiologischen Diagnostik. Munich: Urban & Fischer Verlag, 2000.